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ABSTRACT
Limited parent/caregiver (P/C) knowledge regarding BCAA inborn errors of metabolism
(IEM) could negatively impact patients’ serum BCAA levels, resulting in adverse health
outcomes. This study’s purpose was to identify relationships between P/C’s demographics and
understanding of BCAA IEM to patient’s serum leucine level. Participants included P/C and
patients with a BCAA IEM. During patients’ appointments, questionnaires were administered to
P/Cs eliciting understanding of BCAA IEM and demographics. Regression analyses estimated
relationships between P/C understanding of BCAA IEM and demographic factors to patients’
serum leucine levels. No correlation was observed between P/C understanding of BCAA IEM
and patient’s serum leucine level. However, number of children in the household, P/C age, and
P/C’s employment status were significant, and potentially predictive of patients’ leucine levels.
Despite possible relationships of these demographic factors to patient’s leucine levels, it is
imperative that P/Cs adhere to disease-management recommendations to ensure their children’s
best health outcomes.
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CHAPTER 1: REVIEW OF THE LITERATURE
Introduction
The branched-chain amino acids (BCAA) are comprised of the amino acids leucine
(Leu), isoleucine (Ile), and valine (Val). They are metabolized in most cells, including skeletal
and hepatic muscle tissues, and serve as important sources of energy during physical activity and
periods of stress, as well as precursors in amino acid and protein synthesis pathways.1-5 Removal
of an amino group via the branched-chain amino acid aminotransferase (BCAT) enzyme is the
first step in the catabolism of BCAAs. This first reaction produces branched-chain keto-acids.
Next, the branched-chain keto-acid dehydrogenase (BCDH) enzyme catalyzes the second step of
the degradation of a BCAA into an α-ketoacid. Eventually, the resulting α-ketoacid undergoes
oxidative phosphorylation, and continues to the form coenzyme A (CoA). The CoA can be
further complexed to form Acetyl-CoA (AcCoA) from leucine.1,6 The resulting AcCoA enters
the citric acid cycle to generate energy in the form of adenosine triphosphate (ATP), generate
cholesterol and triacylglycerols from fatty acids, or create ketone bodies via ketogenesis for
energy production in the absence of glucose.
Known dysfunctions in BCAA metabolism are inherited via an autosomal recessive
pattern, meaning two copies of a mutated gene must be present in order for the condition or trait
to develop.7 Errors in the pathway of leucine metabolism include maple syrup urine disease
(MSUD), isovaleric academia (IVA), 3-methylcrotonyl-CoA carboxylase deficiency (3 MCC),
and 3-methylglutaconyl-CoA hydratase deficiency (3 MGC), whereas dysfunction in the
metabolism of valine and other essential amino acids result in methylmalonic aciduria (MMA)
and propionic acidemia (PA). These disorders of organic acid metabolism can lead to limited
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systemic, cognitive, neurological, and/or motor development.8 These and other amino acid
disorders are commonly referred to as inborn errors of metabolism, or inherited metabolic
disorders.
Physiological Effects
Pathophysiology of BCAA metabolic disorders include: accumulation and toxic effects of
specific metabolites, metabolic imbalances, transport competition, metabolic intermediates and
micronutrient deficiencies, and mitochondrial alterations associated with disordered energy
production and oxidative stress.7 The accumulation of toxic metabolites, such as leucine in
MSUD or methylmalonic acid in MMA, leads to significant alterations related to metabolism and
energy homeostasis that are also associated with clinical symptoms.7,9,10 Clinical symptoms of
decompensation and other disease-related complications range in severity from hypotonia and
failure to thrive to acute and life-threatening encephalopathy. For instance, accumulation of
leucine and its associated metabolites result in deleterious alterations in aerobic metabolism in
the brain due to compromised enzymatic activity in individuals with MSUD.7,11 The toxic
intermediates of alternative proprionate oxidation inhibit various enzymatic actions. Oxidative
phosphorylation that is inhibited in the mitochondria is an example of a complication related to
enzymatic activities. When oxidative phosphorylation is inhibited, energy production is limited
and complications such as neurological distress, cardiomyopathy, or renal insufficiency
occur.7,12,13 Several mechanisms, including mitochondrial dysfunctions, substrate imbalances,
and toxic effects of serum ammonia and other specific metabolites, contribute to the
pathophysiology and clinical presentation of BCAA metabolic disorders.7
Inborn errors of metabolism have been included in newborn screening protocols in order
to identify enzyme deficiencies, or dysfunctions, specific to disorders of amino acid and organic
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acid metabolism. Inclusion of these conditions in neonatal screening tests also prevents severe
neurological impairment and intellectual and developmental disability.
Newborn Screening
In the 1960s, scientist and researcher Robert Guthrie introduced the concept of newborn
screening diagnostic procedures for early identification of inherited metabolic disorders. The
early tests required a single blood spot on a filter paper card that was used in various assays.14,15
Initially, Guthrie developed a screening test for phenylketonuria (PKU), a disorder of
phenylalanine metabolism that can lead to severe neurological impairment and, historically,
institutionalization if left untreated.14,16 These screening practices were adopted in most
developed countries, demonstrating clear and successful measures for preventing severe
neurological deterioration by initiating a dietary phenylalanine restriction. As newborn screening
programs evolved, criteria were established for incorporation into newborn screening programs:
disease frequency in the population, ability to treat the disease, management of disease, and cost
of the screening test.14,17 Clinical outcomes for children identified with conditions included in the
newborn screening program, and subsequently treated, were significantly improved and they
were able to lead relatively normal lives with implementation of dietary restriction and
therapeutic interventions.
These strategies for newborn screening remained constant for many decades; however,
using a single blood spot for screening protocols limited the number of conditions that could be
included in the screening test.14 Tandem mass spectrometry was introduced in the 1990s as an
alternative technique for newborn screening, and is currently the most commonly utilized
laboratory test in newborn screening programs. This technique is used to analyze biomarkers,
specific amino acids and acylcarnitines in blood samples, for detecting many more metabolic
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conditions, including amino, organic, and fatty acid metabolism disorders.14,18 Utilization of
tandem mass spectrometry allows for the inclusion of conditions beyond that which various
assays could identify. Using the property of multiple reaction monitoring allows for the
simultaneous observations of multiple different compounds using a single bloodspot, which
allowed for the expansion of newborn screening protocols. Additionally, tandem mass
spectrometry and multiple reaction monitoring allows for the inclusion of several rare conditions
that could not be included in Guthrie’s bloodspot assays due to significantly increased cost.14
It is generally accepted that blood samples for newborn screening tests be collected
between 24-48 hours following the birth of infants. Tandem mass spectrometry is then performed
to evaluate specific amino acids and acylcarnitines in the collected blood samples. If the
screening test suggests a flaw in a metabolic pathway, such as an abnormal level of specific
amino acids and acylcarntitines compared to established reference standards, further enzymatic
or genetic tests are performed to confirm a diagnosis.18 For example, mass spectrometry cannot
differentiate acylcarnitine isomers and metabolites, thus its necessary use as an initial screening
tool. The presence of, or increase in, acylcarnitine C3 may suggest methylmalonic aciduria or
proprionic aciduria. To distinguish between these two inherited metabolic disorders, further
enzymatic or genetic testing is required to identify which specific disorder to diagnose.15,19-21
After identifying the specific metabolic disorder, treatment for the confirmed genetic condition
can be identified and implemented.15,22-24
Treatment Strategies
Treatment options for inborn errors of metabolism are often long-term and conservative
therapies. These include restricting precursor amino acids and protein, replenishing deficient
substrates, and using antioxidants and anaplerotic agents (intermediates that refill the citric acid
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cycle). Fundamentally, treatment goals for BCAA metabolic disorders seek to build up the
intermediates for various metabolic pathways and prevent decompensation by maintaining
anabolic mechanisms. Disease-specific therapies reduce metabolite toxicity, promote anabolism,
replace deficient substrates, and stimulate enzymatic activity while activating alternative
metabolic pathways. Furthermore, these therapies must be adapted for the complex nature of
these conditions and modified for individual patient needs.7Biochemically, treatment for
metabolic conditions should maintain normal protein synthetic pathways while preventing
protein catabolism, and mitigate imbalances and deficiencies of amino acids and intermediates
for metabolic pathways, avoid cellular dysfunctions, restore energy homeostasis, and increase
anabolic pathways.7
There are two identified treatment objectives: acute-phase treatment and chronic
management. After the diagnosis is established, long-term management of the patient’s condition
should be initiated. Treatment is comprised of a specific dietary therapy that reflects thoughtful
adjustment of energy and protein intake. Micronutrient and vitamin supplementation may be
recommended. In some cases, adjunct therapies, such as carnitine supplementation, are needed to
meet specific needs of the patient.7,25-29
Dietary treatment for inborn errors of metabolism is centered on an intake pattern that is
described as ‘low natural protein with adequate or high-energy’ that is also combined with
disease-specific mixtures of amino acids. Specialized amino acid formulas lacking particular
amino acids, and their precursors, have been designed for individuals with specific metabolic
disorders. Most formulas are also enriched with necessary vitamins, minerals, and fatty acids to
maintain general health. Combining natural protein restriction with special medical foods
supports normal growth and development and corrects nutritional deficiencies.7,30,31 Feeding
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difficulties have also been observed among patients with BCAA metabolic disorders and are
associated with muscular hypotonia, nausea, decompensation, infection, and intellectual or
development disability.7,25,32 Failure to thrive may be an observed complication among patients
with inherited metabolic conditions. Severe restriction of particular amino acid precursors and
natural protein, micronutrient deficiencies, and increased energy requirements due to prolonged
illnesses or inflammation can also be associated with conditions of failure to thrive.7,30,31
Adjunct Therapies
Including adjunct therapies with metabolic formulas is an effective strategy for long-term
management of inherited metabolic disorders. Carnitine supplementation has been identified as
an effective means for preventing carnitine deficiency, regenerating the intracellular pool of free
CoA, and eliminating toxic intermediates.7,28 Carnitine is essential for transporting long-chain
fatty acids into the mitochondria for fatty acid β-oxidation. Furthermore, carnitine can help clear
acyl-CoA elements and organic acids from the cell.7,33 Carnitine also exhibits antioxidant
properties that are similar to that of α-tocopherols.7,34
Lower intracellular concentrations of proprionic and methylmalonic acids, and acyl CoA
fractions have been observed following treatment with carnitine. Carnitine therapy may also
directly reduce oxidative damage, as well as maintain enzymes related to energy metabolism.
Thus, there appears to be a convincing rationale for the use of carnitine in patients with
metabolic disorders such as MMA, PA, or IVA.7,28,35 However, carnitine supplementation in
patients with MSUD has not been identified as therapeutically useful.7,36
Other adjunct therapies include use of α-tocopherols and ascorbate. Experimental data
collected from animal models suggest that utilization of α-tocopherols (vitamin E) or ascorbate
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(vitamin C) may contribute to lower oxidative stress among individuals with BCAA metabolic
disorders.7,11,37
Possible Future Treatment Options
Animal models of MSUD (iMSUD) can survive beyond weaning and are useful models
for future therapeutic research and investigation.7,38,39 For instance, nonphysiological amino acid
norleucine has been tested for its action in preventing BCAA accumulation in the brain,
particularly leucine. Zinnanti, et al., also found that norleucine supplementation delayed
encephalopathy in iMSUD mice that were fed a high-protein diet, reduced brain α-ketoisocaproic
acid levels, and preserved energy metabolism. These possible benefits were displayed following
the identification of near-normal pyruvate and α-keto glutaric acid concentrations.7,38 Hepatocyte
transplantation in iMSUD mice has also been found to regulate particular neurometabolic
irregularities in both dopaminergic and serotoninergic systems. Furthermore, increased lifespan
and body weight were observed following hepatocyte transplantation in iMSUD mice, which
suggests a possible therapeutic purpose in humans diagnosed with MSUD.7,40,41
Mice with a severe form of MMA, without mutation (Mut -/-), have been successfully
treated with hepatocyte-directed delivery of a methylmalonyl-CoA mutase (Mut) gene. About
half of the mice that received an intrahepatic injection of the Mut gene lived beyond one year,
whereas nearly all of the non-treatment mice were deceased within 21 days following birth.
Studying further alterations in mitochondrial status and antioxidant defenses can also be
characterized in this mouse model leading to new treatment approaches.7,42 In similar fashion,
mice models with PA (Pcca -/-) who receive Pcca gene transfer also found an improvement in
survival rate and reduction in gene-related metabolites.7,43 Together, these findings in newborn
MMA (Mut -/-) and PA (Pcca -/-) mice suggest that neonatal gene transfer may represent future
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therapies that are beneficial in achieving improved metabolic outcomes among newborns
diagnosed with MMA or PA.
Liver transplantation has also been examined as a possible treatment measure for MMA.
The primary aim of liver transplantation for inherited metabolic disorders is to save a patient’s
life when a metabolic disorder is expected to progress to organ failure. Kayler, et al.,
retrospectively analyzed pediatric patients with liver transplants who were diagnosed with
MMA, and discovered that pediatric liver transplantation led to improvement in clinical and
biochemical outcomes compared to those who did not receive transplantation. Serum
methylmalonic acid concentrations in the brain decreased compared to preoperative levels
among those with MMA. Additionally, liver transplantation has been found to eliminate lifethreatening episodes of ketoacidosis that is a defining characteristic of MMA. However, Kaplan,
et al., reported that liver transplantation is not curative for MMA. It was further noted that
accumulation of methylmalonic acid concentrations in the brain continue to increase due to de
novo synthesis of proprionyl-CoA within the central nervous system. Continuing damage to the
kidneys and brain resulting in renal insufficiency and neurological impairment, respectively,
occurs despite successful transplantation.44-47 Thus, liver transplantation for patients with MMA
may help to manage the condition while not being curative.48
While liver transplantation may not provide a curative treatment for MMA or PA, it may
provide a cost effective method for managing the conditions. Li, et al., concluded that liver
transplantation is a less costly disease management strategy compared to nutritional support for
newborns diagnosed with MMA or PA. The cost savings was likely to be significant to society,
as well as for families managing either MMA or PA. Medical foods are extremely expensive,
and, in most states, are not typically covered for those over 18 years of age. Out-of-pocket costs
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such as dietary management, special education, and living assistance can be significant burdens
for families and individuals who manage such inborn errors of metabolism. Li, et al., rationalized
that liver transplant patients no longer require special medical foods or high-dose supplements
and developmental and long-term health outcomes may contribute to decreased need for special
services and resources, which offset societal and out-of-pocket costs for managing inherited
metabolic conditions such as MMA or PA. 49
Quality of Life
Inborn errors of metabolism requiring dietary restriction impact the quality of life of both
parents and children affected by inherited metabolic conditions.50-53 Using the World Health
Organization Quality of Life (WHOQOL) questionnaire, Fabre, et al. determined that both
parents of children and children with metabolic disorders reported lower scores on the physical
dimension of the WHOQOL as compared to those without inborn errors of metabolism. Fabre,
et.al.’s research also suggested that physical aspects of quality of life are more impacted
compared to psychological aspects. This could be related to multiple coping strategies that are
adopted by parents and families of those managing chronic diseases.50,54
Fabre, et al. determined that dietary restrictions are partially responsible for parents’
reporting on the WHOQOL, as indicated in comments within the food preparation section of the
questionnaire. Parents reported that minute weighing and logistics become complicated. Some
parents also reported that they feel well prepared for potential patient illnesses, but preparing for
holidays and leisure activities is far more difficult. Additionally, limited diet was a complaint
shared by both parents and children. Food habits related to culture play a large role among
families; and, parents commented on the inability of sharing certain meals limits family and
cultural celebrations. It was also noted that children diagnosed with metabolic conditions, as well
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as families, find little pleasure in consuming food. Furthermore, dietary management is a lifelong stress.50
While diet restriction can lead to stressors experienced by parents and families of
children diagnosed with inherited metabolic disorders, events related to newborn screening can
also be correlated to stressors experienced by parents and families. Using the Parental Stress
Index, Weisbren, et al., observed that mothers whose children were diagnosed with metabolic
disorders at newborn screening reported experiencing less overall stress as compared to mothers
whose children were diagnosed in a clinical setting.55 These mothers are also likely to experience
fewer stressors later in life as their children would begin treatment for their metabolic disorders
earlier in life, which contributes to long-term patient outcomes and improved neurological and
motor development as compared to children diagnosed in a clinical setting later in life.
Conclusion
Inherited metabolic disorders such as MSUD, MMA, PA, IVA, etc. are genetic disorders
that, if left untreated, can result in irreversible developmental and intellectual disabilities. Many
treatments and outcomes have been studied in children with these conditions; however, lack of
parent/caregiver knowledge could significantly and negatively impact a child’s serum BCAA
levels and result in multiple health risks, adverse health outcomes, and decreased quality of life.
The purpose of this study is to determine if there is a relationship between parent/caregiver
knowledge and understanding of their child’s inherited metabolic disorder and diet treatment
practices and the serum levels of BCAAs among children in their care.

10

CHAPTER 2: METHODS
Research Participants
The research participants included patients and parents or primary caregivers of patients
who have been diagnosed with a BCAA metabolic disorder, specifically MSUD, IVA, 3 MCC, 3
MGC, MMA, or PA. These patients are followed and monitored by a physician/geneticist and
registered dietitian/nutritionist from the University of Tennessee Health Science Center’s
(UTHSC) Boling Center for Developmental Disabilities (BCDD). During a scheduled
appointment, the parents or caregivers (referred to as parent/caregiver or parents/caregivers)
were asked for their consent to participate in the research study. After consent was obtained,
parents/caregivers completed a questionnaire that sought to determine their understanding of
their child’s disease and the care required to manage the condition. There were a total of 21
possible participants.
Research Design
Patients whose inherited metabolic disorders are managed by the UTHSC BCDD staff are
seen periodically for follow-up of their condition. These follow-up appointments include a blood
draw to measure various laboratory values, including the patient’s serum leucine level, a
nutrition assessment completed by the staff registered dietitian/nutritionist, and a physical
examination performed by the physician/geneticist. Parents and guardians are asked to bring a
three-day food record for the patient, which is reviewed with the registered dietitian/nutritionist
during the appointment and later analyzed using MetabolicPro software. The dietary analysis is
used to compare the laboratory measures with macronutrient and specific amino acid intake to
determine if an updated nutrition prescription is needed in order to maintain serum leucine levels
within treatment range.
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Following the dietitian/nutritionist’s nutrition assessment interview, the patient’s
parent/caregiver was invited to participate in the research study and sign a consent form
(Appendix A). In some cases, the patient interacted with the parent/caregiver as responses were
being made. After consent was given, a questionnaire was provided to the parent/caregiver,
whose responses were marked on the survey instrument (Appendix B). Because it was uncertain
whether the questionnaire would be returned to the researcher in a timely manner, the
questionnaire was completed during the time of the patient’s appointment. The questionnaire
used was developed by modifying a previous survey instrument and included questions related to
demographic information and parent/caregiver understanding of BCAA metabolic disorders. Six
questions regarding parent/caregiver understanding were used to assess parent/caregiver
knowledge regarding BCAA metabolic disorders and associated dietary treatment, which was
ascertained by the number of correct responses on the questionnaire. Eight additional questions
elicited information regarding daily nutritional management of the child’s BCAA metabolic
disorder. After the questionnaire was completed, the patient’s medical record was reviewed and
the mean serum leucine level from the previous six clinic visits was calculated and recorded.
Content Validation
The questionnaire used for data collection was developed by modifying a previously-used
survey instrument, and included questions specific to parent/caregiver understanding of BCAA
metabolic disorders and demographic information. Dr. Lee Wallace, registered
dietitian/nutritionist at the BCDD, reviewed the survey items specific to parent/caregiver
understanding of BCAA metabolic disorders. Following extensive discussion and feedback, Dr.
Wallace and the student researcher believed the questionnaire met an appropriate literacy level
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for study participants and the survey items to be valid and appropriate for data collection
purposes.
Statistical Methods and Data Analysis
Patients’ mean serum leucine levels and data collected from the participant
questionnaires were analyzed using R statistical software. Multiple regression was utilized to
estimate predictive relationships between the parent/caregiver understanding of BCAA metabolic
disorders and demographic information of the families who completed the questionnaire to
patients’ mean serum leucine levels.

13

CHAPTER 3: RESULTS
Statistical analyses using R software were performed to identify relationships of patients'
mean serum leucine levels to parent/caregiver survey scores and various demographic factors. Of
the expected 21 possible participants (parents/caregivers and adult patients), only 11 participants
were interviewed and included in the data analysis. Table 1 outlines baseline demographic
information and characteristics of the 11 participants.
Table 1: Participants’ demographic information
Age Group
18-29 years
30-39 years
40-49 years
50-59 years
60-69 years
70-79 years

n
1 (9%)
4 (36%)
4 (36%)
1 (9%)
1 (9%)
0 (0%)

Number of
Children

n

Education Level

n

1 (9%)
5 (45%)
2 (18%)
2 (18%)
1 (9%)
0 (0%)

Middle school
Partial high school
Completed high school
Some college
Completed 2-year degree
Completed 4-year degree
Some graduate school
Graduate school
Professional or terminal degree

0 (0%)
1 (9%)
2 (18%)
0 (0%)
3 (27%)
2 (18%)
0 (0%)
3 (27%)
0 (0%)

n

Marital Status

n

0
1
2
3
4
5

Employment
Status
Part-time
Full-time
Retired
Unemployed

1 (9%)
6 (54%)
0 (0%)
4 (36%)

Income Level
<$5000
$5,000-$14,999
$15,000-$24,999
$25,000-$34,999
$35,000-$44,999
$45,000-$54,999
$55,000-$64,999
$65,000-$74,999
$75,000-$84,999
$85,000-$94,999
>$95,000

Single
Married
Divorced
Widowed
Co-inhabitants
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n
1 (9%)
1 (9%)
3 (27%)
1 (9%)
2 (18%)
1 (9%)
0 (0%)
0 (0%)
1 (9%)
1 (9%)
0 (0%)

5 (45%)
6 (54%)
0 (0%)
0 (0%)
0 (0%)

Linear regression was utilized to explore the relationship between patients’ mean serum
leucine levels with parental knowledge of branched-chain amino acid metabolic disorders via
questionnaire score. The parent/caregiver survey score was not a significant predictor of serum
leucine (p = 0.987), indicating no correlation between survey score and patient’s mean leucine
level. Furthermore, the coefficient of determination, or r2, was extremely low (r2 = 3.23e-05),
suggesting that the linear regression model did not provide a good fit to the data. Table 2
demonstrates parent survey scores with associated patients’ mean serum leucine levels.
Table 2: Patient's mean serum leucine level and parent/caregiver survey scores.
Patient’s Mean Serum
Leucine Level (µg/L)
650
388
187
79
511
85
82
59
516
370
44

Survey Scores
6/6 (100%)
6/6 (100%)
6/6 (100%)
6/6 (100%)
5/6 (83.3%)
5/6 (83.3%)
5/6 (83.3%)
5/6 (83.3%)
3/6 (50%)
3/6 (50%)
3/6 (50%)

Multiple regression was used to estimate the relationship of parent/caregiver survey score
and demographic information such as parent/caregiver age, number of children in the household,
parent/caregiver employment status, household income, parent/caregiver education level, and
parent/caregiver marital status to patients’ mean serum leucine level. Estimated correlation
coefficients were observed between mean leucine levels and parent/caregiver age (r = -0.209),
number of children in the household (r = 0.528), and parent/caregiver employment status (r =
0.406), suggesting a significant effect on mean serum leucine levels. The negative correlation
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between mean leucine level and parent/caregiver age suggests that younger parents/caregivers
may be associated with elevated serum leucine levels. Furthermore, the positive relationships
identified between number of children in the household and serum leucine level suggests that
fewer children in the household may be associated with lower serum leucine levels. Similarly,
the positive correlation between parent/caregiver employment status and mean serum leucine
level suggests that families with an unemployed parent/caregiver may be associated with lower
serum leucine levels. Tables 3 and 4 illustrate the regression coefficients of parent survey score
and demographic information to mean serum leucine levels using a full model and a model of
best fit, respectively.
Table 3: Relationship of parent/caregiver survey score and demographic information to mean
serum leucine levels with a full model.
Variable
Parent Survey Score
Parent Age
Number Children in
Household
Employment
Income
Education
Marital Status
*p<0.05

Regression
Coefficients
-15.91
-85.03

Regression
Coefficient p-values
0.688
0.048*

Correlation
Coefficients
-0.209

182.24

0.013*

0.528

182.61
-22.83
26.08
10.61

0.012*
0.130
0.368
0.919

0.406
-

Table 4: Relationship of parent/caregiver demographic information to mean serum leucine levels
with a model of best fit.
Variable
Parent Age
Number Children in
Household
Employment
*p<0.05, **p<0.01

Regression
Coefficients
-86.07

Regression
Coefficient p-values
0.0270*

159.33

0.0013**

156.84

0.0017**
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Testing of assumptions using residual analysis indicated that model assumptions were
violated, specifically an assumption of constant variance. In attempt to “address the assumption
violations, a variance stabilizing transformation (a log transform) was used on mean leucine
score.”56 Using the log values, parent/caregiver age, number of children in the household, and
parent/caregiver employment were significant. A model was fit with parent/caregiver age,
number of children, and parent/caregiver employment. All coefficients were statistically
significant with the log transformation, and an analysis of the residuals was used to determine if
violations in the model assumptions remained. The residual plots improved and the transformed
leucine levels were used for the remaining regressions. Table 5 displays the regression
coefficients of parent/caregiver age, number of children in household, and parent/caregiver
employment to the log of the mean serum leucine levels.56
Table 5: Relationship of parent/caregiver age, number of children in the household, and
parent/caregiver employment to log of mean serum leucine level.
Variable
Parent Age
Number Children in
Household
Employment
*p<0.05 **p<0.01

Regression
Coefficients
-0.3872

Regression
Coefficients p-values
0.015941*

0.7735

0.000406**

0.6747

0.001096**

Thus, number of children in the household (p<0.01) and parent/caregiver employment status
(p<0.01) and parent/caregiver age (p<0.05) were found to be significant with and without
adjustments, and may be predictive of patients’ mean leucine levels.
A full model including two-way interaction terms was fit and none of the interactions
were significant. No interaction terms were found to be statistically significant, and when the
interaction terms were included in the model, the main effects were determined not be significant
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as well. No coefficients of determination, r2, were greatly reduced in the interaction models,
indicating a poor fit. These outcomes suggest that a model with interaction terms is not
appropriate for this data.56
While six items sought to determine parent/caregiver knowledge and understanding of
their child’s BCAA metabolic disorder, the remaining items elicited information regarding daily
management of the patient’s nutrition needs. Research participants selected the responses that
most closely describe their usual habits and daily nutrition management strategies. These
responses are recorded and presented in tables 6 and 7.
Table 6: Nutrition management of BCAA metabolic disorders.
Response

Item
I understand the diet prescription given to
my child.
I understand how to follow my child’s diet
prescription.
I feel comfortable mixing (or supervising)
my child’s formula each day.
I know how much leucine or protein from
natural foods my child is allowed to eat
each day.
I know which foods my child is not
allowed to eat.
I know how to find which foods my child
is allowed to eat.
After receiving the results of my child’s
lab values, I monitor my child’s diet with
extra care if the leucine is high.

Yes

No

10

1

10

1

11

0

10

1

11

0

11

0

10

1

It should be noted that participants were allowed to choose more than one response for the items
questions presented in table 7. Therefore, there are more than 11 responses presented.
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Table 7: Patients’ nutrition care management and participation.
Number of Response
Selections

Question
My child’s diet is managed by…
a. Counting leucine.
b. Counting protein.
c. Using an exchange system.
d. Consuming a prescribed formula each day.
e. I don’t know.
My child participates in his/her care by…
a. Mixing his/her formula after the appropriate amounts
are measured.
b. Consuming all of his/her formula.
c. Helping with his/her food records.
d. My child is too young to participate in his/her care
management.
e. My child does not help in his/her care management.

1
6
0
5
1
5
7
3
1
2

It was observed that the majority of responses presented in table 6 were ‘Yes;’ however, one
single participant responded ‘No’ to four items and ‘Yes’ to three. After further investigation, it
was observed that the same participant also had the lowest recorded mean serum leucine level
and was tied for the lowest score on the six content questionnaire items. When completing the
statement ‘My child’s diet is managed by…’ the same participant responded with ‘I don’t know.’
This finding may suggest that this patient is unique with regard to managing his or her BCAA
metabolic disorder, or may have a mild variant of his or her inherited metabolic disorder.
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CHAPTER 4: DISCUSSION
Although, research suggests maternal knowledge is correlated with serum phenylalanine
level in children with PKU in their care, parental and caregiver knowledge and demographics
have not been assessed to identify relationships with serum leucine level in children with BCAA
metabolic disorders.57 The student researcher and statistician explored statistical relationships
and interactions between parental understanding of BCAA metabolic disorders and various
demographic factors with patients’ mean serum leucine levels. Identifying these relationships
and interactions was achieved by surveying parents/caregivers about their knowledge of BCAA
metabolic disorders and various demographic information, then determining statistical
relationships and interactions between parent/caregiver survey responses and mean serum
leucine levels from their child’s previous six follow-up health maintenance visits with the
registered dietitian/nutritionist and physician/geneticist.
Student and faculty researchers determined that parent knowledge, as indicated by parent
survey score, was not a significant predictor of serum leucine level, suggesting no correlation
between survey score and patients’ mean leucine level. However, further statistical analysis
determined that parent/caregiver age, number of children in the household, and parent/caregiver
employment status were found to be significant, and may be predictive of patients’ mean serum
leucine levels. It appears that a younger parent/caregiver may have a child with elevated serum
leucine levels. Furthermore, fewer children in the household and families with an unemployed
parent/caregiver are associated with a lower serum leucine level. Because explanations for these
possible predictive relationships cannot be identified at this time, further research is necessary to
determine social explanations for the relationships between parent/caregiver age, number of
children in the household, and parent/caregiver employment status to patients’ mean serum
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leucine levels. Further statistical analysis found that a full model including two-way interaction
terms did not provide a good fit for this data, and none of the interactions have a significant
effect on, or relationship with, mean serum leucine level.
Furthermore, during data collection, it was observed that two BCDD patients with BCAA
metabolic disorders did not have measured serum leucine levels included in their medical charts.
It was later confirmed that these patients are medically stable and have been diagnosed with a
mild variant of their respective conditions. Additionally, they do not require dietary restriction as
part of their medical treatment and therapy. These two patients, out of 21 potential participants,
represent nearly 9% of the patient population with BCAA metabolic disorders treated at the
BCDD. While researchers collected parent/caregiver survey scores and demographic
information, these two patients were excluded from statistical analysis as they did not have
measured serum leucine levels, nor do they require dietary restriction as part of their medical
therapy.
Limitations & Recommendations
The most noteworthy limitation was the study’s sample size. With only 11 participants, it
was difficult to confidently establish predictive relationships or correlations between
parent/caregiver understanding of BCAA metabolic disorders and demographic information and
their child’s mean serum leucine levels with any statistical significance. More meaningful results
may reveal themselves with a larger sample size, which could be accomplished by recruiting
participation from regional genetics centers, which are often associated with hospitals. Because
these centers are the primary healthcare sites for individuals with inherited metabolic disorders,
recruiting their involvement would likely expand the subject pool and offer more meaningful
information related to parent/caregiver understanding of BCAA metabolic disorders and
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demographic information and their possible relationships with patients’ mean serum leucine
levels.
There were a number of occurrences that could be considered limitations related to data
collection. Some research participants were of legal age, and were primarily responsible for the
dietary management of their metabolic disorder; therefore, the patient, rather than his or her
parent/caregiver, provided some survey responses. In other instances, surveys were administered
primarily to a patient’s parent/caregiver and the patient was included in the response gathering.
These situations may have resulted in collecting misleading information related to
parent/caregiver knowledge of his or her child’s BCAA metabolic disorder. Furthermore, these
incidents may have impacted the data by skewing the relationship between parent/caregiver
knowledge of the BCAA metabolic disorder and the patient’s mean serum leucine level.
Both the student researcher and the BCDD faculty advisor participated in data collection
by conducting surveys; therefore, there may have been inconsistencies in how the surveys were
presented and conducted. Furthermore, parents and caregivers have varied educational
backgrounds; thus, the student researcher adjusted her strategy for conducting the survey
interview. While some parents/caregivers completed the questionnaire with little or no assistance
from the student researchers, the student researcher read and paraphrased some questionnaire
items to improve participant understanding and participation for those parents/caregivers with an
apparent lower literacy level. It is reasonable to conclude that some items were more complex
than initially anticipated prior to data collection and lacked an appropriate literacy level for
participants. These circumstances also likely impacted parent/caregiver responses and possibly
altered the relationship between parent/caregiver knowledge and demographic information and
patient’s mean serum leucine level. In future endeavors, it will be imperative to more carefully
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consider the complexity of the questionnaire items, as well as literacy level, when developing a
research questionnaire.
Conclusion
Branched-chain amino acids serve as important sources of energy during periods of stress
and physical activity, as well as precursors for amino acid and protein synthesis pathways.
BCAA metabolic disorders are heritable disorders that, if left untreated, can result in irreversible
developmental and neurocognitive disabilities. These conditions are identified via the newborn
screening program, leading to treatment and therapeutic interventions and resulting in improved
clinical outcomes. Therapeutic treatments include combining natural protein restriction with
special medical foods to support normal growth and development, correct nutritional
deficiencies, and maintain general health. Many treatments and outcomes have been studied in
children with these conditions; however, lack of parent/caregiver knowledge could significantly
and negatively impact a child’s serum BCAA levels and result in multiple health risks, adverse
health outcomes, and decreased quality of life. There was no apparent predictive relationship
between parent/caregiver knowledge and understanding of BCAA metabolic disorders with
patients’ mean serum leucine level. However, number of children in the household, as well as
parent/caregiver age and employment status, was found to be significant with and without
adjustments, and may be predictive of patients’ mean serum leucine levels. Despite the possible
relationship of these social factors to serum leucine levels, the imperative that parents and
caregivers understand and adhere to dietary restrictions and disease therapies specific to BCAA
metabolic disorders to ensure their children’s best neurocognitive, psychosocial, and
physiological outcomes still remain.
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